The aim of this research was to assess the efficacy of the new generation micro-fractional CO2 laser low dose energy (Aphrodite, BH LASER, France) in the treatment of genitourinary syndrome.
Materials and Methods
This prospective interventional clinical study, included a total of 25 menopausal symptomatic patients and 25 non-menopausal symptomatic patients having symptoms of vulvovaginal atrophy. There were only two laser sessions spaced at 6 weeks.
It was evaluated the Female Sexual Function Index (FSFI) and the QoL at baseline, 3 and 6 months.
The study showed a significant improvement in both groups when assessing FSFI scores at 3- and 6-months follow-up compared to baseline (p<0.05) and secondary it was observed a significant initial improvement of QoL score at 3 and 6 months (p<0.05), compared to baseline.
There were no important adverse events registered during the study period.
The new micro-fractionated laser device with low dose energy – 18W, demonstrated significant improvement of genitourinary syndrome in both non-menopausal and post-menopausal women with no important adverse event.Le texte complet de cet article est disponible en PDF.
Keywords : Micro-fractional CO2 laser, Genito-urinary syndrome, Menopause, Vaginal atrophy, Dyspareunia